1. Academic Validation
  2. A defective mechanosensing pathway affects fibroblast-to-myofibroblast transition in the old male mouse heart

A defective mechanosensing pathway affects fibroblast-to-myofibroblast transition in the old male mouse heart

  • iScience. 2023 Jul 4;26(8):107283. doi: 10.1016/j.isci.2023.107283.
Aude Angelini 1 JoAnn Trial 1 Alexander B Saltzman 2 3 Anna Malovannaya 2 3 Katarzyna A Cieslik 1
Affiliations

Affiliations

  • 1 Section of Cardiovascular Research, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
  • 2 Verna and Marrs McLean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX, USA.
  • 3 Mass Spectrometry Proteomics Core, Baylor College of Medicine, Houston, TX, USA.
Abstract

The cardiac fibroblast interacts with an extracellular matrix (ECM), enabling myofibroblast maturation via a process called mechanosensing. Although in the aging male heart, ECM is stiffer than in the young mouse, myofibroblast development is impaired, as demonstrated in 2-D and 3-D experiments. In old male cardiac fibroblasts, we found a decrease in actin polymerization, α-smooth muscle actin (α-SMA), and Kindlin-2 expressions, the latter an effector of the mechanosensing. When Kindlin-2 levels were manipulated via siRNA interference, young fibroblasts developed an old-like fibroblast phenotype, whereas Kindlin-2 overexpression in old fibroblasts reversed the defective phenotype. Finally, inhibition of overactivated extracellular regulated kinases 1 and 2 (ERK1/2) in the old male fibroblasts rescued actin polymerization and α-SMA expression. Pathological ERK1/2 overactivation was also attenuated by Kindlin-2 overexpression. In contrast, old female cardiac fibroblasts retained an operant mechanosensing pathway. In conclusion, we identified defective components of the Kindlin/ERK/actin/α-SMA mechanosensing axis in aged male fibroblasts.

Keywords

Cardiovascular medicine; Molecular microbiology; Pathophysiology.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-101494
    99.93%, ERK1/ERK2 Inhibitor
    ERK